2022
New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol
Lanskey J, Kocagoncu E, Quinn A, Cheng Y, Karadag M, Pitt J, Lowe S, Perkinton M, Raymont V, Singh K, Woolrich M, Nobre A, Henson R, Rowe J. New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol. BMJ Open 2022, 12: e055135. PMID: 36521898, PMCID: PMC9756184, DOI: 10.1136/bmjopen-2021-055135.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentEarly-stage Alzheimer's diseaseCognitive impairmentPeer-reviewed scientific journalsLongitudinal cohort studyResearch Ethics CommitteeAlzheimer's diseaseAmyloid-positive mild cognitive impairmentAlzheimer's disease studyConference presentationsCohort studyMeasures of diseaseCognitive AssessmentDisease StudyStudy protocolPrimary analysisEthics CommitteeLongitudinal changesParticipantsCognitive changesWebsite publicationClinical trial durationNew therapeuticsEast of England-Cambridge Central Research Ethics CommitteeProgression of Alzheimer's disease
2015
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, Blennow K, Olsson M, Hansson O, Hansson O, Minthon L, Toresson H, Nägga K, Palmqvist S, Stomrud E, Johansson P, Nilsson C, Nilsson M, Mattsson N, Lindqvist D, Vestberg S, Janelidze S, Zetterberg H, Blennow K, Andreasson U, van Westen D, Lätt J, Mannfolk P, Nilsson M, Strandberg O, Sundgren P, Ståhlberg F, Lindberg O, Westman E, Wahlund L, Wollmer P, Smith R, Olsson T, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Gamst A, Saykin A, Morris J, Potter W, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Beckett L, Harvey D, Gamst A, Kornak J, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Dolen S, Quinn J, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Tang C, Marzloff G, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts CAN P, Albert M, Kozauer N, Zerrate M, Rusinek H, de Leon M, De Santi S, Doraiswamy P, Petrella J, Aiello M, Arnold S, Karlawish J, Wolk D, Smith C, Given C, Hardy P, Lopez O, Oakley M, Simpson D, Ismail M, Brand C, Richard J, Mulnard R, Thai G, Mc-Adams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Laubinger M, Apostolova L, Silverman D, Lu P, Graff-Radford N, Parfitt F, Johnson H, Farlow M, Herring S, Hake A, van Dyck C, MacAvoy M, Benincasa A, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Wu C, Johnson N, Mesulam M, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Rentz D, Johnson K, Rosen A, Tinklenberg J, Ashford W, Sabbagh M, Connor D, Jacobson S, Killiany R, Norbash A, Nair A, Obisesan T, Jayam-Trouth A, Wang P, Lerner A, Hudson L, Ogrocki P, DeCarli C, Fletcher E, Carmichael O, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Hendin B, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Englert J, Williamson J, Sink K, Watkins F, Ott B, Stopa E, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Mintzer J, Longmire C, Spicer K. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 2015, 85: 1240-1249. PMID: 26354982, PMCID: PMC4607601, DOI: 10.1212/wnl.0000000000001991.Peer-Reviewed Original ResearchConceptsEarly Alzheimer's diseaseCSF biomarkersEarly-stage Alzheimer's diseaseAlzheimer's diseasePET measuresAmyloid PETT-tauMCI-ADPET biomarkersAβ42/P-tauDiagnostic accuracyClass III evidenceΒ-amyloid depositionMild cognitive impairmentHigh diagnostic accuracyAβ depositionP-tauTotal tauAD dementiaCSF Aβ42Patient preferencesCSF measuresEuroimmun ELISAAlzheimer's Disease Neuroimaging Initiative studyBioFINDER study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply